Jump to any asset
844 assets, updated daily
Pfizer vs Merck & Co.
VS
Comparative Analysis
Pfizer (PFE) wins this head-to-head comparison against Merck (MRK) due to its superior profitability and more attractive valuation, despite Merck's stronger recent revenue growth. PFE offers a significantly higher dividend yield and trades at a lower earnings multiple, presenting a more compelling income and value proposition. While MRK has shown better recent earnings beats and a higher return on assets, PFE's strong net profit margin and return on equity, coupled with a more favorable risk-reward profile based on technicals, tip the scales in its favor for income-focused and value-oriented investors. Merck's recent earnings have been volatile, with significant misses in the latest two quarters, impacting its overall earnings quality compared to PFE, which has a more consistent, albeit less spectacular, performance. PFE's technical indicators, including a higher RSI and MACD, suggest stronger current momentum, further solidifying its position as the preferred investment at this juncture. Investors seeking a blend of income and value should favor PFE, while those prioritizing aggressive growth and a higher asset efficiency might lean towards MRK, though with greater earnings risk.
Key Differentiator
The most significant differentiator between Pfizer (PFE) and Merck (MRK) is PFE's superior profitability and income generation capability, evidenced by its higher net profit margin and substantially greater dividend yield. While MRK shows stronger revenue growth and higher analyst targets, PFE's valuation is more attractive, and its technicals suggest more immediate positive momentum. For investors prioritizing a blend of value, income, and current technical strength, PFE stands out as the more compelling choice.
Joint Outlook
The outlook for Pfizer (PFE) is one of steady income generation and potential value appreciation, supported by its strong dividend and more attractive valuation. While its growth may be more moderate, its profitability provides a solid foundation. Merck (MRK) has a higher growth potential, driven by its pipeline and higher revenue growth, but faces increased risk due to earnings volatility and a higher valuation. A scenario for MRK involves successful drug launches driving significant earnings growth, leading to price target outperformance. Conversely, continued earnings misses could lead to a valuation multiple contraction. For PFE, the outlook is more stable, with the primary risk being a potential slowdown in the pharmaceutical sector or unexpected profitability declines impacting its dividend.
Price Analysis Comparison
Valuation Metrics
| Metric | PFE | MRK |
|---|---|---|
| P/E Ratio | 37.33 | 115.44 |
| Market Cap | 161.70B | 350.29B |
| Price/Sales | 2.54 | 5.39 |
| Price/Book | 1.90 | 8.56 |
| EV/EBITDA | 8.43 | 14.05 |
| Dividend Yield | 6.06% | 2.39% |
Pfizer (PFE) presents a more attractive valuation compared to Merck (MRK), trading at a significantly lower P/E ratio of 37.33 versus MRK's 115.44. This suggests that investors are paying less for each dollar of Pfizer's earnings. While both companies have positive revenue growth, PFE's higher net profit margin of 6.8% compared to MRK's 4.77% indicates better operational efficiency in converting revenue into profit. Also, PFE's dividend yield of 6.06% is more than double MRK's 2.39%, making it a more appealing choice for income-seeking investors. MRK's higher median analyst target of $163 compared to PFE's $28.50 suggests that analysts anticipate greater upside for MRK, but this is balanced by its considerably higher valuation multiples and recent earnings volatility.
Profitability & Efficiency
| Metric | PFE | MRK |
|---|---|---|
| Rev. Growth (Qtly) | 2.60% | 5.10% |
| Profit Margin | 6.81% | 4.77% |
| Return on Equity | 5.01% | 6.96% |
| Return on Assets | 5.78% | 11.87% |
| Debt/Equity | 0.74 | 1.28 |
Pfizer (PFE) exhibits stronger profitability metrics than Merck (MRK). PFE boasts a higher net profit margin of 6.8% compared to MRK's 4.77%, indicating superior efficiency in generating profit from its sales. While MRK shows a higher return on assets at 11.87%, PFE's return on equity (ROE) at 5.01% is competitive with MRK's 6.96%, though MRK leads here. The significant difference in net profit margin is a key differentiator, suggesting PFE manages its costs more effectively. This higher margin, combined with a substantial dividend yield, positions PFE favorably for investors prioritizing consistent profitability and income generation.
Earnings Reality Check
PFE
Earnings data unavailable. No recent report data found.
MRK
Last 2 Qs: MRK beat estimates 2x out of 2. Rose 2x after beats.
Technical Indicators
| Indicator | PFE | MRK |
|---|---|---|
| RSI (14) | 66.42 | 54.63 |
| 50-Day MA | $27.83 | $144.43 |
| 200-Day MA | $26.52 | $124.48 |
Pfizer (PFE) shows stronger technical momentum than Merck (MRK). PFE's RSI is at 66.42, indicating firm upward momentum without being overbought, while MRK's RSI is at a more neutral 54.63. PFE's MACD value of 0.21 suggests a bullish trend, whereas MRK's MACD of -0.19 indicates a bearish or neutral trend. Both stocks are trading above their 50-day and 200-day moving averages, confirming an overall uptrend for both. PFE's price is also closer to its 52-week high, trading at $29.21 versus a high of $29.49, suggesting recent strength. MRK, trading at $147.37 against a high of $156.92, shows more room to its 52-week high but less immediate upward pressure.
AI Analyst Sentiment
AI rating: CleaRank Financial AI's overall score for each asset, the same score shown on its own analysis page. It combines price trend and momentum with valuation, analyst and insider data where they exist.
PFE
AI Score: 58/100
MRK
AI Score: 72/100
Analyst sentiment leans slightly more positive towards Merck (MRK), with a median target price of $163 representing a significant upside from its current price, and a rating breakdown of 5 Strong Buys, 14 Buys, and 8 Holds. Pfizer (PFE) has a median target of $28.50, which is below its current trading price, and its analyst ratings are more mixed, with 2 Strong Buys, 8 Buys, 16 Holds, and 1 Sell. This suggests that while analysts see more potential upside in MRK, PFE is viewed as a more stable, albeit less growth-oriented, investment by the analyst community. The market reaction to MRK's recent earnings has been positive on average, despite misses, indicating underlying investor confidence.
Note: While MRK has the higher AI score (Buy 72/100), the AI comparative analysis favors PFE (Hold 58/100) based on its overall trend structure, fundamentals, and risk-adjusted outlook.
Risk Stratification
| Metric | PFE | MRK |
|---|---|---|
| Beta (Volatility) | 0.28 | 0.22 |
| Sharpe Ratio | -0.08 | 0.44 |
Merck (MRK) faces risks related to its recent earnings volatility, with significant misses in two of its last three reported quarters. This suggests potential challenges in forecasting future earnings and could lead to increased stock price fluctuations. Its higher valuation multiples also present a risk if growth expectations are not met. Pfizer (PFE) carries the risk of slower growth compared to MRK, as indicated by its lower revenue growth rate and more conservative analyst targets. Its high dividend yield, while attractive, could be at risk if future profitability falters, although its current net profit margin provides a buffer. Both companies operate in the highly regulated pharmaceutical sector, facing risks from drug development failures, patent expirations, and government policy changes.
Comparative ProTips
- Consider PFE for its attractive dividend yield and lower valuation multiples, suitable for income-focused portfolios.
- Monitor MRK's earnings reports closely; consistent beats could justify its higher valuation, but misses increase downside risk.
- Both stocks are trading above key moving averages, suggesting a generally positive sector trend, but PFE's technicals show stronger current momentum.
Monte Carlo Projection (10yr)
Simulated growth of $10,000 in each asset, from its own historical volatility and trend. Statistical outcomes, not forecasts.
Actionable Trade Plans
Compare entry, exit, and risk management levels for both assets
Select Your Trade Bias
Risk Tolerance
Conservative
3%
Aggressive
Portfolio Value
$
✎
Position Size: $200 - $300 per asset
PFE
Current: $29.21
ENTRY ZONES
Conservative
$27.75
Aggressive
$29.21
RISK MANAGEMENT
STOP LOSS
$26.92
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5% from current
$30.67
+10% from current
$32.13
+15% from current
$33.59
MRK
Current: $147.37
ENTRY ZONES
Conservative
$140.00
Aggressive
$147.37
RISK MANAGEMENT
STOP LOSS
$135.80
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5% from current
$154.74
+10% from current
$162.11
+15% from current
$169.48
Calculate Your Trade
Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. The verdict weighs trend, valuation and risk together. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss. Note: The AI favored PFE based on profitability metrics. This is valid for the specified timeframe only. While MRK currently shows the stronger short-term technical score (72 vs 58), the AI favors PFE on the factors above rather than today's technical setup.
Frequently Asked Questions
How do PFE and MRK compare on valuation?+
Pfizer (PFE) is significantly cheaper on a P/E basis (37.33 vs 115.44) and offers a much higher dividend yield (6.06% vs 2.39%). MRK's higher median analyst target suggests potential upside, but its current valuation is less attractive.
Which stock offers better income potential?+
Pfizer (PFE) offers superior income potential with a dividend yield of 6.06%, more than double Merck's (MRK) 2.39%. PFE's higher net profit margin also supports the sustainability of its dividend.
How do their technicals compare?+
Pfizer (PFE) shows stronger technical momentum with a higher RSI (66.42 vs 54.63) and a bullish MACD signal, indicating more immediate upward pressure compared to MRK's more neutral technical stance.
How does their profitability stack up?+
Pfizer (PFE) leads in profitability with a higher net profit margin (6.8% vs 4.77%), indicating better cost management. Merck (MRK) has a higher return on assets, but PFE's margin advantage is a key differentiator for overall profit generation.
How have PFE and MRK performed over the past year?+
Over the 12 months to October 15, 2026, PFE's price rose 19.8% and MRK's rose 75.2%. These are price changes; dividends are not included.
Which is more volatile, PFE or MRK?+
MRK has been more volatile. Over the 30 days to October 15, 2026, PFE's annualized volatility was 17.3% and MRK's 27.5%, measured from daily closing prices.